David Domzalski - Mar 17, 2022 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Role
President and CEO, Director
Signature
/s/ Mutya Harsch, attorney-in-fact for David Domzalski
Stock symbol
VYNE
Transactions as of
Mar 17, 2022
Transactions value $
$0
Form type
4
Date filed
3/18/2022, 05:09 PM
Previous filing
Jan 4, 2022
Next filing
Apr 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYNE Common Stock Award $0 +312K +41.06% $0.00 1.07M Mar 17, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VYNE Stock Options Award $0 +312K $0.00 312K Mar 17, 2022 Common Stock 312K $0.61 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of VYNE Therapeutics Inc.
F2 The awards vest over four years, 25% on March 31, 2023 and 6.25% every three months thereafter, ending on March 31, 2026.